Response to Comment on Pietropaolo et al. Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2- Infected Young Individuals: Is It Type 1 Diabetes? Diabetes 2022;71:2656-2663.

Pietropaolo, Massimo; Hotez, Peter; Giannoukakis, Nick

Pietropaolo, Massimo; Hotez, Peter; Giannoukakis, Nick.

Pietropaolo M; Diabetes Research Center, Section of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston, TX.
Hotez P; Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX.
Giannoukakis N; Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, PA.

Diabetes ; 71(12): e19, 2022 Dec 01.

Article in English | MEDLINE | ID: covidwho-2198222

Subject(s)

COVID-19; Diabetes Mellitus, Type 1; Humans; Insulin/therapeutic use; Diabetes Mellitus, Type 1/complications; Diabetes Mellitus, Type 1/drug therapy; SARS-CoV-2; Incidence; Insulin, Regular, Human; Syndrome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / COVID-19 Type of study: Observational study Topics: Long Covid Limits: Humans Language: English Journal: Diabetes Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google